Genetic Technologies Ltd. ADR (GENE): Price and Financial Metrics
GET POWR RATINGS... FREE!
GENE Stock Summary
- With a market capitalization of $19,760,685, GENETIC TECHNOLOGIES LTD has a greater market value than just 8.47% of US stocks.
- With a year-over-year growth in debt of -59.48%, GENETIC TECHNOLOGIES LTD's debt growth rate surpasses just 4.07% of about US stocks.
- Revenue growth over the past 12 months for GENETIC TECHNOLOGIES LTD comes in at 86,990.22%, a number that bests 99.98% of the US stocks we're tracking.
- Stocks with similar financial metrics, market capitalization, and price volatility to GENETIC TECHNOLOGIES LTD are MRSN, NCTY, MDGS, ARQQ, and VACC.
- Visit GENE's SEC page to see the company's official filings. To visit the company's web site, go to www.gtglabs.com.
GENE Stock Price Chart Interactive Chart >
GENE Price/Volume Stats
| Current price | $1.06 | 52-week high | $2.40 |
| Prev. close | $1.07 | 52-week low | $0.83 |
| Day low | $1.06 | Volume | 111,868 |
| Day high | $1.10 | Avg. volume | 2,613,392 |
| 50-day MA | $1.19 | Dividend yield | N/A |
| 200-day MA | $1.26 | Market Cap | 20.39M |
Genetic Technologies Ltd. ADR (GENE) Company Bio
Genetic Technologies Ltd. is a molecular diagnostics company that offers predictive testing and assessment tools to help physicians proactively manage women's health. It operates through the USA and Australia geographical segments. The firm's product BREVAGenplus, is a clinically validated risk assessment test for non-hereditary breast cancer. The company was founded on January 5, 1987 and is headquartered in Fitzroy, Australia.
Latest GENE News From Around the Web
Below are the latest news stories about GENETIC TECHNOLOGIES LTD that investors may wish to consider to help them evaluate GENE as an investment opportunity.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on ThursdayWe're starting off another day of trading with a look at the biggest pre-market stock movers investors need to watch for Wednesday! |
New Publication Highlights geneType’s Ability to Detect Breast Cancer Earlier and Provide Data for Risk StratificationMELBOURNE, Australia, Feb. 09, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”) – a global leader in genomics-based tests in health, wellness and serious disease – is pleased to announce the publication of a new research paper in the peer-reviewed journal Breast Cancer Research and Treatment. Highlights: GeneType outperforms 5-year and remaining lifetime risk prediction compared to the commonly used clinical models Gail and IBISv7, respectively.The |
Genetic Technologies Announces Closing of $5 Million Registered Direct OfferingMELBOURNE, Australia, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX:GTG; NASDAQ:GENE, “Company”, “GTG”, or “Genetic Technologies”), a global leader in guideline-driven genomics-based tests in health, wellness and serious diseases, today announced the closing of its previously announced registered direct offering with several institutional investors for the purchase and sale of 3,846,155 American Depositary Shares (“ADSs”), each representing six hundred (600) ordinary shares |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on MondayWe're starting off the week with an overview of the biggest pre-market stock movers traders need to know about for Monday! |
Genetic Technologies to Launch Ground-breaking Comprehensive Risk Test for Breast & Ovarian CancerMELBOURNE, Australia, Feb. 06, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in genomics-based tests in health, wellness and serious disease, is delighted to provide further update. The innovation and development of this test is inspired by direct response and feedback from the payer conversations such as insurance providers, employers, and healthcare providers. There is an unmet need to develop a unique single saliva risk asses |
GENE Price Returns
| 1-mo | -21.48% |
| 3-mo | 3.92% |
| 6-mo | -24.29% |
| 1-year | -48.24% |
| 3-year | -37.28% |
| 5-year | -79.30% |
| YTD | 13.98% |
| 2022 | -50.53% |
| 2021 | -47.78% |
| 2020 | 80.90% |
| 2019 | -9.54% |
| 2018 | -52.59% |
Continue Researching GENE
Want to see what other sources are saying about Genetic Technologies Ltd's financials and stock price? Try the links below:Genetic Technologies Ltd (GENE) Stock Price | Nasdaq
Genetic Technologies Ltd (GENE) Stock Quote, History and News - Yahoo Finance
Genetic Technologies Ltd (GENE) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...